Promega

Promega Kit Enables European Forensic Labs to Solve Challenging Cold Cases

Retrieved on: 
星期二, 五月 7, 2024
Health, Biometrics, Health Technology, Genetics, Other Science, Science, Biotechnology, Multimedia, Spectrum, STR, DNA, Promega

Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples.

Key Points: 
  • Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples.
  • The PowerPlex® 18E System, launched by Promega Corporation, uses eight-color short tandem repeat (STR) analysis chemistry to extract more usable information from challenging samples.
  • The kit includes all DNA markers recommended by the European Network of Forensic Science Institutes (ENFSI).
  • “This kit meets European forensic laboratories’ unique needs while also giving them more information from challenging DNA samples compared to earlier chemistries.”
    STR analysis is the most widely used tool in human identification efforts.

Kimberly-Clark Professional™ Announces Greenovation Awards for Sustainability Leadership and Waste Reduction

Retrieved on: 
星期二, 四月 30, 2024
Promega, Environmental health, Safety, Water, Pall Corporation, Kimberly-Clark, PPE, Plastic, Recycling, Renewable energy

ROSWELL, Ga., April 30, 2024 /PRNewswire/ -- Kimberly-Clark Professional™ announced the 2024 Greenovation Awards to recognize 56 companies for demonstrating sustainability leadership and reducing environmental impact by participating in a landfill diversion program.

Key Points: 
  • Partnering with Kimberly-Clark has helped us to maintain that commitment and achieve our sustainability goals."
  • Corey Meek, corporate responsibility program manager of Promega Corporation, said, "Promega has a long-standing commitment to sustainability and environmental stewardship.
  • "Our customers have displayed exceptional leadership in sustainability through this program as well as other initiatives to reduce their environmental impact," said Ashley Davis, global sustainability manager, Kimberly-Clark Professional.
  • "We commend them on their accomplishments and wish them continued success on their sustainability journeys."

Human Identification Market Worth $1.3 billion | MarketsandMarkets™

Retrieved on: 
星期二, 四月 16, 2024
Pulse, Investment, Promega, Competition, QIAGEN, Complete Genomics, Research, Growth, South Korea, Criminology, DNA, Thermo Fisher Scientific, Government, Market development, Risk management

The break-up of the profile of primary participants in the human identification market:

Key Points: 
  • The break-up of the profile of primary participants in the human identification market:
    Get 10% Free Customization on this Report:
    Human Identification Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall human identification market and the subsegments.
  • The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the human identification market.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the human identification market across varied regions.

Human Identification Market Worth $1.3 billion | MarketsandMarkets™

Retrieved on: 
星期二, 四月 16, 2024
Pulse, Investment, Promega, Competition, QIAGEN, Complete Genomics, Research, Growth, South Korea, Criminology, DNA, Thermo Fisher Scientific, Government, Market development, Risk management

The break-up of the profile of primary participants in the human identification market:

Key Points: 
  • The break-up of the profile of primary participants in the human identification market:
    Get 10% Free Customization on this Report:
    Human Identification Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall human identification market and the subsegments.
  • The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the human identification market.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the human identification market across varied regions.

North America Molecular Diagnostics Market Size, Share & Trends Analysis Report 2024-2030: Growing Prevalence of Target Diseases & Increasing External Funding for R&D Fueling Expansion - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 26, 2024
Health, Biotechnology, Candidiasis, Diagnosis, PCR, MVP, Conditional sentence, Bacterial vaginosis, Prevalence, Infection, Promega, Country, Thermo Fisher Scientific, SME, Tuberculosis, Application, ISH, RT, HIV, Alzheimer's disease, Incidence, Turner syndrome, Cepheid variable, Research, Trichomoniasis, Real-time, Cancer, Death, Parkinson's disease, CDC, QIAGEN, Therapy, USD, Horvitz–Thompson estimator, Helix, DSM-IV codes, Vaccine

Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.

Key Points: 
  • Advancements in molecular diagnostic technology enabled the early detection of numerous diseases and reduced the possibility of severe economic & social burdens.
  • Molecular diagnostics enable early diagnosis of cancer, genetic disorders, and infectious diseases by using PCR, sequencing, & genetic technologies.
  • In addition, the increasing incidence of diseases, such as influenza A & B, is projected to drive market growth.
  • An increase in external funding to conduct clinical studies in molecular diagnostics is anticipated to fuel the market.

Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics

Retrieved on: 
星期三, 三月 27, 2024
Eclipse, Health, Biotechnology, Growth, Promega, Research, GMP, CRISPR, Therapy, FDA, RNA, Pharmaceutical industry

REDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately. Craig Christianson has been appointed Chief Executive Officer following an extensive search process. Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor. Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR.

Key Points: 
  • Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor.
  • Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR.
  • "Founding and growing Synthego the past 12 years has been the privilege of a lifetime," said Dabrowski.
  • As the world enters the era of CRISPR based therapeutics, Synthego is now focused to be the premier supplier to hundreds of programs entering the clinic."

Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences

Retrieved on: 
星期四, 二月 22, 2024
Health, Stem Cells, Health Technology, Genetics, Research, Science, Biotechnology, Promega, Sigma-Aldrich, CRISPR, Doctor of Philosophy, Sequence, Marketing, QIAGEN Silicon Valley, QIAGEN, Antibody, Biofuel, Biology, DNA

Ansa Biotechnologies, Inc. , a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.

Key Points: 
  • Ansa Biotechnologies, Inc. , a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.
  • Gammack is joining the company as it completes its early access program for complex synthetic genes and gene fragments and prepares for a full commercial service launch.
  • Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.
  • Ansa’s proprietary DNA synthesis platform is based on precise enzymatic reagents that enable ultra-rapid and controlled single-base additions to a DNA molecule.

BioLabs and Promega Announce Collaboration to Support Young Biotech Companies

Retrieved on: 
星期三, 十二月 13, 2023
Health, Genetics, Other Science, Research, Science, Pharmaceutical, Biotechnology, R, Biolab, Incubator, Knowledge, Partnership, Promega

BioLabs and Promega today announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.

Key Points: 
  • BioLabs and Promega today announced the expansion of their collaborative efforts to accelerate life science innovation worldwide through support for early-stage start-up companies.
  • Promega GmbH in Walldorf, the German branch of global life science manufacturer Promega, will provide equipment, services and training to BioLabs Heidelberg.
  • The global exchange of knowledge between the start-ups and Promega scientists plays a central role, underscoring why Promega prioritizes support for incubators such as BioLabs, says Dr. Hans-Joachim Mueller, General Manager of Promega GmbH.
  • “We can bring Promega products directly into the development process of start-up companies so they can more quickly bring their technologies to market.”
    Nicolas Bardonnet, General Manager of Promega France, says Promega support of BioLabs in Europe is reaffirmed by outcomes witnessed in the US.

Promega Named a BioSpace 2024 Best Places to Work Winner

Retrieved on: 
星期三, 十一月 8, 2023
Other Manufacturing, Human Resources, Professional Services, Manufacturing, Stem Cells, Biotechnology, Health, Other Science, Science, News, Research, Engineering, Human resources, Multimedia, Information technology, Marketing, The Last Best Place, Corporation, Culture, Management, Promega

Promega Corporation has been named a BioSpace 2024 Best Place to Work.

Key Points: 
  • Promega Corporation has been named a BioSpace 2024 Best Place to Work.
  • View the full release here: https://www.businesswire.com/news/home/20231107534836/en/
    Promega Corporation is a BioSpace 2024 Best Place to Work.
  • (Graphic: Business Wire)
    “We're thrilled to be recognized by BioSpace as one of the Best Places to Work in 2024,” says Gayle Paul, Vice President, Human Resources at Promega.
  • BioSpace, a digital hub for life sciences news and careers, has compiled its Best Places to Work list for three years.

In Vitro Toxicology Testing Market Worth $17.1 billion | MarketsandMarkets

Retrieved on: 
星期五, 十月 27, 2023
MEA, Creative Biolabs, Eurofins Scientific, Pharmacology, Promega, Catalent, Patent, Intertek, Islamic finance products, services and contracts, Food, Charles River Laboratories, LATAM, Toxicology, Genetics, Absorption, Acquisition, Tissue engineering, Maintenance, Research, Protein, Phototoxicity, Software, Metabolism, Drug development, SGS, Growth, Thermo Fisher Scientific, Marketing, Merck Group, Agilent Technologies, Animal, Gene, Corrosion, Safety, Investment, Labcorp, Toxicity, Chemical safety, ADME, Medical device, Pharmaceutical industry, Fine chemical

By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.

Key Points: 
  • By product and service, the In vitro toxicology testing market has been further categorized as consumables, assays, equipment, software, and services.
  • In 2022, the ADME segment accounted for the largest share of the in vitro toxicology testing market.
  • The pharmaceutical & biopharmaceutical segment accounted for the largest share of the industry segment in the in vitro toxicology testing market in 2022.
  • In 2022, the pharmaceutical & biopharmaceutical industry segment accounted for the largest share of the in vitro toxicology testing market.